Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23330866 | 0.89 | CHEK1 (0.43) | ALDH1A1SMN1; SMN2LMNATSHRHTT | |
| SCHEMBL23330835 | 0.87 | BRAF (0.36) | SMN1; SMN2HPGDPOLB | |
| SCHEMBL23331259 | 0.85 | MEN1 (0.40) | ALDH1A1SMN1; SMN2LMNATSHRHTT | |
| SCHEMBL23330674 | 0.83 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2LMNATSHRHTT | |
| SCHEMBL23331251 | 0.80 | PTK2 (0.39) | KDM4EHSD17B10POLB | |
| SCHEMBL23330666 | 0.78 | ABL1 (0.39) | ALDH1A1KMT2AKDM4EHSD17B10POLB | |
| SCHEMBL23331245 | 0.77 | P2RX7 (0.40) | SMN1; SMN2KMT2AGAAPOLB | |
| SCHEMBL23330832 | 0.77 | NFKB1 (0.34) | ALDH1A1GAA | |
| SCHEMBL23330663 | 0.77 | SMN1; SMN2 (0.34) | ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL23330660 | 0.76 | SMN1; SMN2 (0.41) | ALDH1A1SMN1; SMN2TSHRHTTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028221-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| WO-2021083380-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海科技大学 | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028221-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP4F11, CYP4A11, HSD11B1 | ALDH1A1 650/4885SMN1; SMN2 4572/4885LMNA 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.